Healthcare -
Biotechnology - NASDAQ - US
$ 1.825
2.3 %
$ 66.9 M
Market Cap
-0.45
P/E
1. INTRINSIC VALUE
FINANCIALS
Balance Sheet
Inovio Pharmaceuticals, Inc.
| Current Assets | 97.8 B |
| Cash & Short-Term Investments | 94.1 B |
| Receivables | 1.2 M |
| Other Current Assets | 3.72 B |
| Non-Current Assets | 15.4 B |
| Long-Term Investments | 1.61 B |
| PP&E | 11.8 B |
| Other Non-Current Assets | 1.98 B |
| Current Liabilities | 35.3 B |
| Accounts Payable | 6.44 M |
| Short-Term Debt | 2.5 B |
| Other Current Liabilities | 32.8 B |
| Non-Current Liabilities | 9.37 B |
| Long-Term Debt | 9.38 B |
| Other Non-Current Liabilities | -9.37 M |
EFFICIENCY
Earnings Waterfall
Inovio Pharmaceuticals, Inc.
| Revenue | 218 K |
| Cost Of Revenue | 0 |
| Gross Profit | 218 K |
| Operating Expenses | 113 M |
| Operating Income | -112 M |
| Other Expenses | 107 B |
| Net Income | -107 B |
RATIOS
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Inovio Pharmaceuticals, Inc.
| Net Income | -107 B |
| Depreciation & Amortization | 3.13 M |
| Capital Expenditures | 0 |
| Stock-Based Compensation | 6.6 M |
| Change in Working Capital | -2.66 M |
| Others | 3.17 B |
| Free Cash Flow | -104 B |
Wall Street Analysts Price Targets
Inovio Pharmaceuticals, Inc.
Wall Street analysts predict an average 1-year price target for INO of $22.7 , with forecasts ranging from
a
low of
$8 to a high of $40 .
INO Lowest Price Target
Wall Street Target
8 USD
338.36%
INO Average Price Target
Wall Street Target
22.7 USD
1142.01%
INO Highest Price Target
Wall Street Target
40 USD
2091.78%
4. DIVIDEND
ANALYSIS
0.00%
DIVIDEND YIELD
0.069 USD
DIVIDEND PER SHARE
5. COMPETITION
6. Ownership
Insider Ownership
Inovio Pharmaceuticals, Inc.
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Bet on These 5 Top-Ranked Stocks With Rising P/E
Tap five stocks with increasing P/E ratios to try out an out-of-the-box approach. These stocks include Carvana, Context Therapeutics Inc, Inovio Pharmaceuticals, ChargePoint and MSA Safety Inc.
zacks.com
- 1 week ago
Inovio (INO) Upgraded to Buy: Here's What You Should Know
Inovio (INO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
zacks.com
- 3 weeks ago
INOVIO to Present at Upcoming Scientific Conferences
PLYMOUTH MEETING, Pa. , April 9, 2025 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that it will highlight key data associated with its lead candidate, INO-3107, at several upcoming conferences, including an opportunity to join other leading voices at the inaugural National HPV Conference.
prnewswire.com
- 3 weeks ago
Down -11.41% in 4 Weeks, Here's Why You Should You Buy the Dip in Inovio (INO)
Inovio (INO) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
zacks.com
- 1 month ago
Inovio Pharmaceuticals, Inc. (INO) Q4 2024 Earnings Call Transcript
Inovio Pharmaceuticals, Inc. (NASDAQ:INO ) Q4 2024 Earnings Conference Call March 18, 2025 4:30 PM ET Company Participants Jennie Willson - IR Jacqui Shea - President & CEO Mike Sumner - Chief Medical Officer Steve Egge - Chief Commercial Officer Peter Kies - CFO Conference Call Participants Roy Buchanan - Citizens JMP Jay Olson - Oppenheimer Sudan Loganathan - Stephens Yi Chen - H.C. Wainwright Anish Nikhanj - RBC Liang Cheng - Jefferies Operator Good afternoon, ladies and gentlemen, and welcome to the Inovio Pharmaceuticals Fourth Quarter 2024 Financial Results Conference Call.
seekingalpha.com
- 1 month ago
INOVIO Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Highlights
Significant progress toward submitting a biologics license application (BLA) for INO-3107 as a potential treatment for recurrent respiratory papillomatosis (RRP) Resolved previously announced manufacturing issue concerning the single-use array component of the CELLECTRA device and completed drafting of all non-device BLA modules On track to begin rolling submission of BLA in mid-2025 and to request priority review with goal of completing the submission in the second half of 2025 and receiving acceptance of the submission by end of the year Announced durability data from retrospective study showing that 50% of patients achieved a Complete Response in the second 12-month period (year 2) with 86% of patients showing a reduction in surgery of 50% or greater in year 2; data to be included in BLA submission Announced promising interim results from ongoing proof-of-concept Phase 1 trial showing DNA-encoded monoclonal antibodies (DMAb) targeting COVID-19 were well tolerated and exhibited long-lasting in vivo production DMAb technology has the potential to overcome traditional monoclonal antibody production challenges, such as short half-life and anti-drug immune responses, making it a potentially promising platform for a broad range of diseases DNA Medicine technology has the potential to provide long term production of therapeutic antibodies and deliver a broad spectrum of therapeutic proteins that could be used to treat diseases with missing or defective proteins PLYMOUTH MEETING, Pa. , March 18, 2025 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced its financial results and operational highlights for the fourth quarter and full year ended December 31, 2024 and provided a business update and description of operational highlights during the year.
prnewswire.com
- 1 month ago
INOVIO Announces Promising Interim Results from Ongoing Proof-of-Concept Clinical Trial of DNA-Encoded Monoclonal Antibodies (DMAbs) for COVID-19
Long-lasting in vivo antibody production: DMAb levels remained stable for 72 weeks in all participants (n=24) who have reached that timepoint No anti-drug antibodies (ADA): no immune rejection of the DMAbs was detected across ~1,000 blood samples, unlike other gene-based antibody delivery approaches where ADA formation has been a challenge Well-tolerated: most common side effects were mild, temporary injection site reactions such as pain and redness; no serious adverse events (SAEs) related to study drug Effective target binding: expressed DMAbs successfully bound to the SARS-CoV-2 Spike protein receptor-binding domain (RBD), confirming functional activity through week 72 PLYMOUTH MEETING, Pa. , March 13, 2025 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced promising interim results from an ongoing Phase 1 proof-of-concept trial evaluating DMAbs for COVID-19.
prnewswire.com
- 1 month ago
INOVIO to Report Fourth Quarter and Year End 2024 Financial Results on March 18, 2025
PLYMOUTH MEETING, Pa. , March 12, 2025 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancers, and infectious diseases, today announced that fourth quarter and year-end 2024 financial results will be released after the market close on March 18, 2025.
prnewswire.com
- 1 month ago
Inovio Pharmaceuticals Inc (INO) Oppenheimer 35th Annual Healthcare Life Sciences Conference (Transcript)
Inovio Pharmaceuticals Inc (NASDAQ:INO ) Oppenheimer 35th Annual Healthcare Life Sciences Conference February 12, 2025 3:20 PM ET Company Participants Jacqui Shea - CEO and President Conference Call Participants Jay Olson - Oppenheimer Jay Olson And our discussion with Inovio. It's a pleasure to introduce Jacqui Shea, CEO and President.
seekingalpha.com
- 2 months ago
Here's Why Inovio (INO) Could be Great Choice for a Bottom Fisher
Inovio (INO) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
zacks.com
- 2 months ago
Clinical and Immunological Results from Phase 1/2 Study of INO-3107 as a Treatment for Recurrent Respiratory Papillomatosis Published in Nature Communications
Data shows that INO-3107 induced new populations of T cells in the blood that traveled to airway tissue and were associated with clinical benefit as measured by reduced need for surgeries PLYMOUTH MEETING, Pa. , Feb. 12, 2025 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that peer-reviewed data from its Phase 1/2 clinical trial with INO-3107 as a potential treatment for recurrent respiratory papillomatosis (RRP) were published online in Nature Communications under the title DNA immunotherapy for recurrent respiratory papillomatosis (RRP): phase 1/2 study assessing efficacy, safety, and immunogenicity of INO-3107.
prnewswire.com
- 2 months ago
Immune Response Data for INO-3107 to be Presented as a Poster at American Association for Cancer Research Immuno-Oncology (AACR-IO) Conference
Poster will describe loss of detectable HPV-6 in Recurrent Respiratory Papillomatosis patients following treatment with INO-3107 PLYMOUTH MEETING, Pa. , Feb. 10, 2025 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that an abstract describing the immunological activity of INO-3107 will be presented as a poster at the following scientific conference: American Association for Cancer Research – Immuno-Oncology Discovery and Innovation in Cancer Immunology: Revolutionizing Treatment through Immunotherapy (February 23-26, 2025) Poster entitled: "Loss of Detectable HPV-6 Following Induction of Emergent T cells in Patients with Durable Complete Clinical Response to Treatment for Recurrent Respiratory Papillomatosis using INO-3107" The abstract will be made available on INOVIO's website following the conference.
prnewswire.com
- 2 months ago
8. Profile
Summary
Inovio Pharmaceuticals, Inc. INO
COUNTRY
US
INDUSTRY
Biotechnology
MARKET CAP
$ 66.9 M
Dividend Yield
0.00%
Description
Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids. The company engages in conducting and planning clinical studies of its DNA medicines for HPV-associated precancers, including cervical, vulvar, and anal dysplasia; HPV-associated cancers, such as head and neck, cervical, anal, penile, vulvar, and vaginal; other HPV-associated disorders, including recurrent respiratory papillomatosis; glioblastoma multiforme; prostate cancer; HIV; Ebola; Middle East Respiratory Syndrome (MERS); and Lassa fever. Its partners and collaborators include ApolloBio Corp., AstraZeneca, Beijing Advaccine Biotechnology Co., Ltd., The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations (CEPI), Defense Advanced Research Projects Agency (DARPA), Department of Defense (DoD), HIV Vaccines Trial Network, International Vaccine Institute, Kaneka Eurogentec, Medical CBRN Defense Consortium (MCDC), National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Ology Bioservices, the Parker Institute for Cancer Immunotherapy, Plumbline Life Sciences, Regeneron Pharmaceuticals, Thermo Fisher Scientific, University of Pennsylvania, Walter Reed Army Institute of Research, and The Wistar Institute. The company has an agreement with Richter-Helm BioLogics GmbH & Co. KG to support investigational DNA vaccine INO-4800 for COVID-19; and a partnership with International Vaccine Institute and Seoul National University Hospital. The company was founded in 1979 and is headquartered in Plymouth Meeting, Pennsylvania.
Contact
660 West Germantown Pike, Plymouth Meeting, PA, 19462
https://www.inovio.com
IPO
Date
Dec. 8, 1998
Employees
134
Officers
Mr. Robert L. Crotty J.D.
General Counsel & Chief Compliance Officer
Mr. E. J. Brandreth MBA
Senior Vice President of Quality Assurance
Dr. Jeffrey Skolnik
Senior Vice President of Clinical Development
Dr. Laurent M. Humeau Ph.D.
Chief Scientific Officer & Chairman of the Scientific Advisory Board
Mr. Peter D. Kies
Chief Financial Officer
Dr. Jacqueline E. Shea Ph.D.
Chief Executive Officer, President & Director
Mr. Shawn D. Bridy M.A., M.B.A.
Senior Vice President of Business Development
Dr. Michael Sumner M.D.
Chief Medical Officer
Thomas Hong
Manager of Investor Relations
Mr. Robert J. Juba Jr.
Senior Vice President of Biological Manufacturing & Clinical Supply Management